The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) will hold a press conference on 6 July 2010 at 10 am at the Olympic Museum in Lausanne, Switzerland, on the occasion of the signing of a Joint Declaration on Cooperation in the Fight against Doping in Sport between the two organizations.
The IFPMA-WADA Joint Declaration will be signed by Mr. Haruo Naito, President of the IFPMA and President and CEO of Eisai Co., Ltd., and Mr. David Howman, Director General of WADA.
During the press conference, Mr. Naito and Mr. Howman will outline the importance of this active cooperation in the fight against doping in sport and will answer media questions. Dr. Yves Juillet, Chair of the Regulatory Policy and Technical Standards Committee of IFPMA, and Dr. Olivier Rabin, Science Director of WADA, will also be available to answer questions.
Media representatives interested in attending the press conference are requested to register prior to July 2 by sending an e-mail to Frédéric Donzé (email@example.com), Senior Manager, Media Relations & Communications of WADA, with the following details: name, title, media organization, e-mail and phone number.
Journalists who wish to conduct one-on-one interviews with Mr. Naito, Mr. Howman, Dr. Juillet and/or Dr. Rabin following the press conference are asked to indicate with their registration which of these representatives they would like to interview.
Date: 6 July 2010
Time: 10:00 – 11:00 am
Auditorium of the Olympic Museum
1 Quai d’Ouchy
About the IFPMA
The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical industry, including the biotech and vaccine sectors. Its members comprise 25 leading international companies and 46 national and regional industry associations covering developed and developing countries. The industry’s R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal (www.ifpma.org/ClinicalTrials), the IFPMA’s Ethical Promotion online resource (www.ifpma.org/EthicalPromotion/) and its Developing World Health Partnerships Directory (www.ifpma.org/HealthPartnerships) help make the industry’s activities more transparent. The IFPMA supports a wide range of WHO technical activities, notably those relating to medicine efficacy, quality and safety, and coordinates industry participation in the WHO IMPACT initiative to combat counterfeit medicines. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
The World Anti-Doping Agency (WADA) is the international independent organization created in 1999 to promote, coordinate and monitor the fight against doping in sport in all its forms. The Agency is composed and funded equally by the sports movement and governments of the world. Its key activities include scientific research, education, development of anti-doping capacities and monitoring of the World Anti-Doping Code - the document harmonizing regulations regarding anti-doping in all sports and all countries.